Summary: Singapore is currently facing an unprecedented demographic crisis, with its total fertility rate dropping to a historic low of 0.87. In response, the government has allocated substantial public funds, including S$37 billion under the Research, Innovation and Enterprise 2030 (RIE2030) masterplan, toward biomedical sciences and technological innovation. Among emerging medical technologies, in vitro gametogenesis (IVG)—the creation of human gametes from pluripotent stem cells—has been touted as a revolutionary solution to severe infertility. However, this paper argues that it is unwise and a profound waste of taxpayer money for Singapore to invest in the research and development of IVG for clinical applications in assisted human reproduction. Firstly, the demographic impact of assisted reproductive technologies is mathematically limited and cannot reverse the national fertility decline. Secondly, immense scientific barriers, including risks of genetic and epigenetic abnormalities, place human clinical translation decades away. Furthermore, allocating public funds to experimental IVG incurs massive opportunity costs, diverting resources from proven social services and broader healthcare needs. Crucially, Singapore’s highly restrictive laws governing assisted reproduction—specifically the bans on surrogacy, the exclusion of same-sex couples from accessing fertility treatments, and strict limits on the number of donor offspring—will severely stifle the commercial viability, profitability, and return on investment of any domestic IVG enterprise. Ultimately, rather than funding speculative domestic research, Singapore should adopt a "wait-and-license" strategy, allowing larger nations to bear the R&D costs and importing the technology only upon maturation. Public funding should instead be redirected toward holistic, socio-economic fertility policies and broader healthcare needs.
Keywords: In Vitro Gametogenesis; Assisted Reproductive Technology; Singapore Fertility Policy; Research Funding Allocation; Reproductive Ethics; Health Economics
1. Introduction
Singapore is confronting a profound demographic crisis that threatens its long-term economic sustainability, national defense capabilities, and overall societal structure. The city-state’s total fertility rate (TFR) has been on a relentless downward trajectory for decades, plummeting to an unprecedented historic low of 0.87 in 2025, a significant drop from 0.97 in 2024 [1]. This figure is drastically below the population replacement level of 2.1, prompting urgent governmental action to galvanize societal support and formulate comprehensive policy interventions. As a nation devoid of natural resources, Singapore relies entirely on its human capital to drive its economic engine. Consequently, the rapid aging of the population and the shrinking citizen workforce have elevated the fertility crisis from a mere sociological concern to an issue of national survival [2].
In an attempt to maintain its competitive edge and address complex national challenges, the Singapore government has heavily prioritized investments in research and development. Under the recently unveiled Research, Innovation and Enterprise 2030 (RIE2030) masterplan, the government has committed a record S$37 billion (approximately US$29.3 billion) over five years [3]. A significant portion of these funds is earmarked for the Health and Biomedical Sciences domain, continuing the legacy of previous RIE plans that sought to position Singapore as a premier global hub for medical research and biotechnology [4]. Within this well-funded ecosystem, there is a growing temptation to channel public resources into cutting-edge medical technologies that promise to alleviate infertility, thereby ostensibly addressing the nation's demographic woes.
One of the most highly anticipated emerging technologies in this field is in vitro gametogenesis (IVG). IVG refers to the laboratory process of manipulating pluripotent stem cells—either embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) derived from adult somatic cells, such as skin cells—to differentiate into mature spermatozoa and oocytes [5]. The foundational proof-of-concept for this technology was established by researchers in Japan, who successfully reconstituted the entire process of oogenesis and spermatogenesis in mice, resulting in the birth of live, fertile offspring [6] [7]. Proponents of IVG argue that translating this technology to humans could revolutionize reproductive medicine by providing an inexhaustible supply of gametes. It holds the theoretical promise of treating absolute infertility (such as premature ovarian insufficiency or azoospermia), allowing same-sex couples to have genetically related children, and eliminating the need for invasive egg retrieval procedures [8].
Despite these alluring prospects, this research paper argues that it is fundamentally unwise and a wasteful expenditure of taxpayer money for Singapore to invest in the research and development of IVG technology for clinical applications in assisted human reproduction. A critical analysis reveals that the pursuit of IVG is fundamentally flawed on multiple fronts. First, the mathematical reality of assisted reproductive technology (ART) dictates that medical interventions cannot significantly alter macroeconomic demographic trends. Second, the scientific and biological barriers to human translation are immense, with clinical applications likely decades away due to severe safety and ethical concerns. Third, the opportunity costs of funding such speculative and niche biomedical research are unacceptably high when compared to the urgent need for broad-based social and healthcare services. Finally, and most crucially, Singapore’s highly restrictive legal and regulatory framework surrounding ART—which includes strict bans on surrogacy, the exclusion of same-sex couples, and stringent limitations on donor gametes—will inherently cripple the commercial viability and return on investment (ROI) of any domestic IVG enterprise.
2. The Illusion of IVG as a Demographic Panacea
A primary justification often implicitly or explicitly used to secure funding for advanced fertility treatments in Singapore is the desperate need to boost the national birth rate. However, relying on medical interventions like IVG to solve a systemic demographic crisis is a mathematically and sociologically flawed strategy.
2.1 The Limited Contribution of ART to National Birth Rates
While in vitro fertilization (IVF) and other ARTs represent a beacon of hope for individuals struggling with clinical infertility, their overall contribution to a nation's total live births is inherently limited. Global data consistently demonstrates that even in developed nations with highly subsidized and accessible fertility treatments, ART-conceived babies account for a relatively small percentage of total births. For instance, in Australia and New Zealand, ART contributes to approximately 5% of all births [9]. In Japan, a country with the world's highest percentage of babies born through IVF, the figure stands at roughly 5% to 8%, yet Japan continues to suffer from one of the lowest fertility rates globally [10]. Even in Scandinavian countries like Denmark, which possess the most robust public funding for ART, the contribution rarely exceeds 10% [11].
Given that Singapore's TFR has collapsed to 0.87, a contribution of 2% to 5% from ART to total live births is entirely insufficient to reverse the demographic decline [12]. The mathematical reality is that even if the introduction of IVG were to double the success rate of ART—a highly optimistic and unlikely scenario—it would translate to only a marginal absolute increase in the national TFR. IVG is designed to address the most severe and intractable forms of infertility, such as the complete absence of gametes, which constitute only a tiny fraction of the overall infertile population [13]. Therefore, the vast majority of the demographic shortfall cannot be remedied by inventing more complex ways to create embryos in a laboratory.
2.2 Addressing the Root Causes of Low Fertility
The decline in fertility in advanced economies like Singapore is primarily driven by socio-economic factors rather than biological infertility. Extensive sociological research indicates that the plummeting birth rate is deeply intertwined with the high opportunity costs of childbearing, the intense pressures of the education system, soaring costs of living, and the challenges of reconciling female labor force participation with traditional domestic roles [14]. In Singapore, the hyper-competitive economic environment and the emphasis on human capital success have created a system that heavily rewards professional achievement while inadvertently penalizing the time and financial resources required to raise multiple children [10].
Investing billions of taxpayer dollars into biomedical research for IVG addresses none of these root causes. It is a highly specialized medical patch applied to a broad sociological wound. As noted by the International Monetary Fund, raising birth rates in Singapore requires confronting the weaknesses of the underlying socio-economic system, not merely enhancing reproductive technologies [10]. Therefore, framing IVG research as a strategic national investment to combat the demographic crisis is a misallocation of focus and resources.
3. Scientific and Clinical Barriers to Human Translation
Even if the demographic arguments were set aside, the sheer scientific and clinical hurdles facing the translation of IVG from animal models to human patients make it a highly risky and speculative investment for public funds.
3.1 The Chasm Between Mouse Models and Human Application
The enthusiasm surrounding IVG is largely predicated on the landmark successes achieved in murine (mouse) models, which have successfully demonstrated the theoretical viability of the procedure [6]. However, the translation of developmental and reproductive biology from mice to humans is notoriously fraught with failure, and the leap from a laboratory mouse to a human patient is monumental. Human gametogenesis is an incredibly complex, prolonged, and highly regulated process that differs significantly from that of rodents in terms of timeline, hormonal regulation, and genetic checkpoints. In human females, for instance, oogenesis begins during fetal development and arrests for decades before ovulation, whereas the process in mice occurs over a matter of weeks.
While researchers have managed to generate human primordial germ cell-like cells (hPGCLCs) from pluripotent stem cells, coaxing these cells to undergo the critical process of meiosis—the specialized cell division that halves the chromosome number—and subsequently mature into fully functional, fertilizable human sperm and eggs remains an unsolved scientific challenge [5] [15]. The intricacies of human meiosis, including homologous recombination and chromosome segregation, are highly prone to error even under natural physiological conditions, leading to aneuploidies such as Down syndrome. Attempting to replicate this delicate dance in an artificial culture medium introduces a massive vector for catastrophic chromosomal errors.
Furthermore, the process in mice is highly inefficient and requires specific biological scaffolding. Current protocols necessitate the use of fetal gonadal somatic cells to provide the necessary supporting environment (the "niche") for the germ cells to develop and mature [7]. Replicating this supportive niche in humans raises profound ethical, legal, and logistical issues, as it would potentially require the harvesting and use of human fetal tissue. Alternatively, it would demand the incredibly complex bioengineering of artificial human ovaries and testes using synthetic scaffolds or organoid technology [8]. The development of such artificial gonads is a monumental scientific hurdle in its own right. Because of these immense biological, methodological, and ethical barriers, leading experts in the field widely estimate that the clinical application of IVG in humans is at least 10 to 20 years away, if it is achievable at all [16]. This timeline renders any immediate public investment highly speculative and unlikely to yield near-term clinical benefits.
3.2 Severe Biological Safety and Epigenetic Risks
Beyond the technical challenges of generating the gametes, the most critical barrier to the clinical use of IVG is the profound and currently unquantifiable risk it poses to the health, development, and long-term well-being of the resulting offspring. The prolonged manipulation of pluripotent stem cells in an artificial laboratory culture environment—subjected to synthetic growth factors, unnatural media, and mechanical stress—exposes the fragile human genome to significant instability. This extensive in vitro culturing raises the alarming specter of accumulating genetic mutations, chromosomal segregation errors (aneuploidy), and, perhaps most concerningly, widespread epigenetic abnormalities [17].
Epigenetic imprinting is a critical biological mechanism by which specific genes are methylated (biochemically tagged) so that they are expressed in a parent-of-origin-specific manner. For normal embryonic development to occur, the epigenetic marks on the DNA must be completely erased in the primordial germ cells and then perfectly re-established during the later stages of gametogenesis according to the sex of the individual producing the gamete [18]. Errors in this incredibly delicate and poorly understood reprogramming process are known to cause severe imprinting disorders in humans. These include devastating developmental conditions such as Beckwith-Wiedemann syndrome, Angelman syndrome, Prader-Willi syndrome, and Silver-Russell syndrome, which are characterized by severe growth abnormalities, neurological deficits, and increased cancer susceptibility [19].
Existing Assisted Reproductive Technologies, such as standard IVF and Intracytoplasmic Sperm Injection (ICSI), are already associated with a slightly elevated risk of these rare imprinting disorders, likely due to the brief period embryos spend in culture media [20]. The risk of such epigenetic aberrations is exponentially magnified in IVG, where the entire lifecycle of the gamete—from somatic cell to iPSC, through meiosis, and into a mature egg or sperm—is conducted entirely in vitro [17]. The artificial environment simply cannot perfectly replicate the dynamic, highly regulated biochemical signaling of the human body.
Due to these severe, unpredictable, and potentially transgenerational risks, the global scientific and bioethics communities have urged extreme caution. The International Society for Stem Cell Research (ISSCR), the premier global authority on stem cell science, explicitly categorizes the use of IVG for human reproductive purposes as a prohibited research activity [21]. Similarly, the Ethics Committee of the American Society for Reproductive Medicine (ASRM) has issued a firm consensus opinion stating that IVG should absolutely not be considered for reproductive purposes in humans until robust, long-term safety data is accumulated from non-human primate models across multiple generations [17]. This would require breeding monkeys using IVG, waiting for them to reach sexual maturity, and then evaluating their offspring for subtle developmental or epigenetic flaws—a process that would take decades. Investing Singaporean taxpayer money into the clinical development of a technology that is currently deemed biologically unsafe and ethically prohibited by international scientific consensus for its ultimate clinical end-goal is a highly questionable and reckless fiscal strategy.
4. The Opportunity Cost of Biomedical R&D in Singapore
In public policy and health economics, every funding decision carries an opportunity cost. The S$37 billion allocated under the RIE2030 plan represents a finite pool of public resources. Channelling a portion of these funds into the protracted, high-risk development of IVG means those funds cannot be deployed elsewhere.
4.1 Diverting Funds from Proven Social Interventions
If the government's ultimate goal in considering funding for advanced fertility technologies is to support family formation and improve the demographic outlook for its citizens, there are far more proven, immediate, and cost-effective avenues for public spending. Extensive sociological and economic studies on pronatalist policies in Singapore and other developed nations have consistently shown that direct financial incentives, robust housing grants, and comprehensive childcare subsidies are the most tangible and effective ways to alleviate the heavy burdens on prospective parents [22].
Expanding universal, heavily subsidized infant care and high-quality preschool education, significantly increasing government-paid parental and paternity leave, and providing even more direct financial support for young couples attempting to secure public housing (HDB flats) would provide immediate, measurable benefits to a massive segment of the population. These social interventions directly address the primary reasons couples delay or forego having children. In stark contrast, IVG research consumes massive amounts of highly specialized scientific capital and funding to develop a niche, highly experimental treatment that will only ever be applicable to a microscopic percentage of the population facing absolute, untreatable biological infertility [13]. Funding IVG at the expense of broad social support is a misallocation of resources that prioritizes speculative science over proven societal welfare.
4.2 Alternative Healthcare Spending Priorities
Within the healthcare sector itself, the opportunity costs are equally stark. Singapore is facing a rapidly aging population, with a consequent surge in chronic diseases, neurodegenerative conditions, and the need for long-term eldercare [23]. Furthermore, mental health services and primary care infrastructure require continuous investment. Allocating public R&D funds to speculative reproductive technologies diverts critical scientific talent and financial capital away from research into age-related diseases, oncology, and preventative medicine—areas that represent the overwhelming majority of the national disease burden. A utilitarian approach to public health economics dictates that taxpayer money should be invested in research that yields the greatest health benefits for the largest number of citizens, a metric by which IVG unequivocally fails.
5. Ethical Dilemmas and Societal Concerns
Beyond safety and economics, IVG introduces a host of profound ethical and societal dilemmas that the Singaporean public has not yet reconciled.
5.1 Commodification of Human Life and Eugenics
The defining characteristic of IVG is its potential to generate a virtually limitless supply of embryos. Unlike traditional IVF, where the number of embryos is strictly limited by the painful and biologically constrained process of ovarian stimulation and egg retrieval, IVG could theoretically allow a clinic to produce dozens or hundreds of embryos from a single skin biopsy [8].
While this abundance could be used to ensure a successful pregnancy, it inevitably opens the door to the commodification of human life. With hundreds of embryos available, prospective parents could utilize preimplantation genetic testing for aneuploidy (PGT-A) and polygenic risk scoring to screen and select embryos not just for the absence of disease, but for desired traits [17]. This introduces the terrifying prospect of consumer-driven eugenics, where embryos are farmed, graded, and discarded on an industrial scale to produce "designer babies." Such practices deeply offend human dignity and threaten to fundamentally alter the moral fabric of society [24].
5.2 Justice, Equity, and the Widening Social Divide
Given the immense technological sophistication required, IVG will undoubtedly be an extraordinarily expensive medical procedure [16]. If developed and commercialized, access to IVG would be strictly limited to the ultra-wealthy. This exacerbates existing social inequalities, creating a dystopian scenario where only the affluent have the means to bypass biological infertility and genetically select their offspring [17]. Using public taxpayer funds—contributed by citizens across all socio-economic strata—to subsidize the research and development of an elitist technology that the vast majority will never be able to afford is a profound violation of distributive justice.
6. Restrictive ART Laws in Singapore: The Death Knell for Commercial Viability and ROI
Perhaps the most compelling argument against public investment in IVG in Singapore is an economic one, rooted in the nation's own legal framework. Biomedical research, particularly under the RIE2030 enterprise pillar, is often justified by its potential for commercialization, patent generation, and the creation of a profitable biotechnology industry [3]. However, the strict laws and regulations governing clinical assisted reproduction in Singapore will severely restrict the market applications of IVG, effectively destroying its profitability and return on investment (ROI).
6.1 The Ban on Surrogacy
Singapore strictly prohibits both traditional and gestational surrogacy [25]. The Ministry of Health explicitly bans licensed healthcare institutions from providing ART services for the purpose of surrogacy. This legal barrier eliminates a significant portion of the potential IVG market. For instance, a woman who lacks a uterus but can produce oocytes via IVG, or a single man who generates both sperm and eggs via IVG, would still require a surrogate to carry the pregnancy to term. Because surrogacy is banned locally, these individuals cannot undergo the full reproductive process in Singapore. Consequently, the domestic market for IVG is artificially truncated, severely limiting the potential patient base and the corresponding revenue streams for any local IVG enterprise.
6.2 The Exclusion of Same-Sex Couples
One of the most highly anticipated applications of IVG globally is its potential to allow same-sex couples to have children that are genetically related to both partners [26]. By deriving oocytes from male somatic cells or spermatozoa from female somatic cells, IVG could revolutionize LGBTQ+ family formation. This represents a massive, highly lucrative, and deeply motivated global market [27].
However, Singapore's family laws and healthcare regulations do not recognize same-sex marriages or partnerships [28]. Furthermore, access to ART procedures, including IVF, is strictly restricted to legally married heterosexual couples [29]. The government has repeatedly stated its policy stance against the formation of same-sex family units [28]. Therefore, the application of IVG for same-sex reproduction will be completely banned in Singapore. By legally excluding one of the largest and most profitable target demographics for IVG, Singapore ensures that any domestic commercialization of the technology will be financially crippled from its inception.
6.3 Limits on Donor Offspring and Mass Production
Another highly profitable potential application of IVG is the mass production of donor gametes. Currently, the global fertility industry suffers from a severe shortage of high-quality donor eggs, driving up costs and creating a lucrative market for donor egg IVF [30]. IVG could theoretically solve this by mass-producing oocytes from the stem cells of selected donors.
However, Singaporean regulations strictly limit the number of children that can be born from a single gamete donor to a maximum of three to five offspring, primarily to prevent accidental consanguinity [31]. This strict legal cap entirely negates the economic advantage of IVG's mass-production capabilities. A biotechnology company cannot monetize the industrial-scale production of donor eggs if it is legally prohibited from selling those eggs to more than a handful of patients. Thus, the strict regulations in Singapore prevent the exploitation of this lucrative commercial market, drastically reducing the potential ROI for investors and the state [13].
In summary, while the global market for IVG may be vast, the addressable domestic market in Singapore is severely constrained by conservative family laws and strict ART regulations. The bans on surrogacy, the exclusion of same-sex couples, and the limits on donor offspring mean that the most profitable applications of IVG are illegal in Singapore. Therefore, investing public R&D funds into a technology whose primary commercial avenues are legally blocked locally is an exceptionally poor financial strategy that guarantees a negative return on taxpayer investment.
7. The Wait-and-License Strategy: A Cost-Effective Alternative
Rather than shouldering the massive financial risks and ethical burdens of developing IVG domestically, Singapore should adopt a "wait-and-license" strategy. This approach, widely recognized in global health economics, involves allowing larger nations with massive biomedical budgets to bear the exorbitant costs of early-stage R&D and clinical trials, while smaller nations adopt the technology only after it has reached clinical maturity and proven its cost-effectiveness [32].
7.1 Leveraging the Free-Rider Advantage in Medical Technology
In the economics of biomedical innovation, the "free-rider problem" often dictates that smaller or developing nations optimally rely on the scientific breakthroughs of larger, wealthier nations [33]. The United States, the European Union, and China currently dominate global biomedical R&D expenditures. Developing complex, high-risk technologies like IVG requires immense capital investments that are difficult to justify for a nation of Singapore's size. By acting as a strategic "free rider," Singapore can avoid the sunk costs of failed clinical trials and speculative research [34].
Once IVG technology is matured, standardized, and proven safe by international regulatory bodies (such as the US FDA or the European EMA), Singapore can import the technology through standard biomedical licensing agreements. This model has been successfully utilized by many developing and middle-income nations to access advanced medical devices and pharmaceuticals without bearing the initial R&D burden [35]. Given that only a tiny fraction of patients with the most severe infertility issues will ever require IVG, awaiting the maturation of the technology and subsequent licensing is a far more cost-effective public healthcare policy.
7.2 Singapore's Proven History as a Technology Adopter
Singapore actually possesses a strong historical precedent for this strategy. During the early stages of its economic development, Singapore thrived not as a primary innovator, but as a highly efficient and rapid adopter of foreign technologies, particularly in electronics and early biomedical manufacturing [36]. The nation’s regulatory body, the Health Sciences Authority (HSA), has established robust frameworks for evaluating and licensing foreign medical technologies based on rigorous health technology assessments (HTA) and cost-effectiveness evaluations [37].
By relying on the HSA to assess the clinical efficacy and economic value of IVG once it is fully developed abroad, the government can ensure that public funds are only spent on purchasing proven treatments. This "wait-and-license" approach aligns perfectly with value-based healthcare pricing models, ensuring that Singaporean taxpayers only pay for medical technologies that deliver measurable health gains, rather than funding the highly uncertain journey of scientific discovery for a niche reproductive procedure.
8. Conclusion
The pursuit of in vitro gametogenesis represents a fascinating frontier in fundamental stem cell biology. However, as a target for public investment under Singapore's RIE2030 biomedical sciences budget, it is a profoundly unwise and wasteful endeavor. The narrative that IVG can rescue Singapore from its demographic crisis is mathematically unfounded; ART contributes only marginally to national birth rates, and IVG addresses only the rarest forms of infertility. Furthermore, the immense scientific barriers, characterized by severe risks of epigenetic and chromosomal abnormalities, place safe human clinical translation decades away.
More importantly, funding IVG incurs unacceptable opportunity costs, diverting billions of taxpayer dollars away from proven social policies—such as childcare, housing, and eldercare—that genuinely support family formation and public health. Singapore’s highly restrictive ART laws, which ban surrogacy, exclude same-sex couples, and limit donor gametes, ensure that the most lucrative global markets for IVG cannot be realized domestically, effectively destroying the commercial viability and ROI of the technology within the city-state.
Instead of funding speculative domestic R&D, Singapore should adopt a cost-effective "wait-and-license" strategy. By allowing larger nations to bear the exorbitant costs of maturing IVG technology, Singapore can import it via standard licensing procedures only after it is proven safe and effective. Given that only a tiny fraction of patients require this technology, this approach represents a far wiser public healthcare policy. Therefore, the Singapore government must exercise fiscal prudence and ethical foresight by refusing to fund IVG R&D, redirecting its vital resources toward holistic, socially-driven solutions that serve the broader needs of its aging population.
References
- Ganesan N. Singapore’s total fertility rate falls to historic low of 0.97. Channel News Asia. 2024 Feb 28. https://www.channelnewsasia.com/singapore/singapore-total-fertility-rate-population-parents-children-4155616
- Osman-Gani AM, Chan TH. Trends and challenges of developing human capital in Singapore: An analysis of current practices and future potentials. Human Resource Development International. 2009;12(1):47–68. https://doi.org/10.1080/13678860802638834
- National Research Foundation Singapore. Research, Innovation and Enterprise 2030. NRF; 2025. https://www.nrf.gov.sg/rie2030/
- EDB Singapore. Singapore invests S$37 billion in RIE2030 research plan; semiconductors, ageing among focus areas. Economic Development Board; 2025 Dec 5. https://www.edb.gov.sg/en/business-insights/insights/singapore-invests-s37-billion-in-rie2030-research-plan-semiconductors-ageing-among-focus-areas.html
- Saitou M, Hayashi K. Mammalian in vitro gametogenesis. Science. 2021;374(6563):eaaz6830. https://doi.org/10.1126/science.aaz6830
- Hayashi K, Ohta H, Kurimoto K, Toma S, Yamaguchi S, Suda T, Nakauchi H, Saitou M. Reconstitution of the mouse germ cell specification pathway in culture by pluripotent stem cells. Cell. 2011;146(4):519-532. https://doi.org/10.1016/j.cell.2011.06.052
- Hikabe O, Hamazaki N, Nagamatsu G, Obata Y, Hirao Y, Hamada N, Shimamoto S, Imamura T, Kishima M, Katsumata M, Suzuki T. Reconstitution in vitro of the entire cycle of the mouse female germ line. Nature. 2016;539(7628):299-303. https://doi.org/10.1038/nature20104
- Cohen IG, Daley GQ, Adashi EY. Disruptive reproductive technologies. Science Translational Medicine. 2017;9(372):eaag2959. https://doi.org/10.1126/scitranslmed.aag2959
- Chambers GM, Hoang VP, Sullivan EA, Chapman MG, Ishihara O, Zegers-Hochschild F, Nygren KG, Adamko A. The impact of consumer affordability on access to assisted reproductive technologies and embryo transfer practices: an international analysis. Fertility and Sterility. 2014;101(1):191-198. https://doi.org/10.1016/j.fertnstert.2013.09.005
- Tan PL. Lessons from Singapore on Raising Fertility Rates. Finance & Development. International Monetary Fund. 2020 Mar. https://www.imf.org/en/publications/fandd/issues/2020/03/lessons-from-singapore-on-raising-fertility-rates-tan
- Kocourková J, Šťastná A. The influence of the increasing use of assisted reproductive technology on fertility trends in Europe. Scientific Reports. 2023;13:10100. https://doi.org/10.1038/s41598-023-37071-7
- Lazzari E, Gray E, Chambers GM. Projecting the Contribution of Assisted Reproductive Technology to Completed Cohort Fertility. Human Reproduction. 2023;38(5):920-930. https://doi.org/10.1007/s11113-023-09765-3
- Heng Boon Chin A. Singapore cannot rely on newly-emerging assisted reproductive technologies (ART) to boost its ultra-low fertility rate. Springer Nature Research Communities. 2025 Jun 12. https://communities.springernature.com/videos/singapore-cannot-rely-on-newly-emerging-assisted-reproductive-technologies-art-to-boost-its-ultra-low-fertility-rate
- Tan J. Perceptions towards pronatalist policies in Singapore. Asian Journal of Social Science. 2023;51(1):1-10. https://doi.org/10.1007/s12546-023-09309-8
- Irie N, Weinberger L, Tang WW, Kobayashi T, Viukov S, Manor YS, Dietmann S, Hanna JH, Surani MA. SOX17 is a critical specifier of human primordial germ cell fate. Cell. 2015;160(1-2):253-268. https://doi.org/10.1016/j.cell.2014.12.013
- Stat News. IVG is promising — but it won't replace IVF quite yet. 2023 Oct 2. https://www.statnews.com/2023/10/02/ivg-ivf-replacement-reproductive-technology-hype/
- Klipstein S, Abhari S, Amato P, et al. Ethical considerations of in vitro gametogenesis: an Ethics Committee opinion. Fertility and Sterility. 2026;125(1):10-18. https://doi.org/10.1016/j.fertnstert.2026.01.006
- Laprise SL. Implications of epigenetics and genomic imprinting in assisted reproductive technologies. Molecular Reproduction and Development. 2009;76(10):1006-1018. https://doi.org/10.1002/mrd.21058
- Gambadauro A, Chirico V, Galletta F, Gulino F. Imprinting Disorders and Epigenetic Alterations in Children Conceived by Assisted Reproductive Technologies: Mechanisms, Clinical Outcomes, and Prenatal Diagnosis. Genes. 2025;16(10):1242. https://doi.org/10.3390/genes16101242
- Hattori H, Hiura H, Kitamura A, Miyauchi N, Kobayashi N, Takahashi S, Okae H, Kyono K, Yaegashi N, Arima T. Association of four imprinting disorders and ART. Clinical Epigenetics. 2019;11(1):21. https://doi.org/10.1186/s13148-019-0623-3
- Clark AT, Brivanlou A, Fu J, Kato K, Mathews D, Niakan KK, Rivron N, Saitou M, Surani A, Tang F, Rossant J. Human embryo research, stem cell-derived embryo models and in vitro gametogenesis: Considerations leading to the revised ISSCR guidelines. Stem Cell Reports. 2021;16(6):1416-1424. https://doi.org/10.1016/j.stemcr.2021.05.008
- Doepke M, Hannusch A, Kindermann M, Tertilt M. The New Economics of Fertility. National Bureau of Economic Research. 2022. https://doi.org/10.1057/9780230226203.1158
- Commonwealth Fund. International Health Care System Profiles: Singapore. 2023. https://www.commonwealthfund.org/international-health-policy-center/system-profiles/singapore
- Nuffield Council on Bioethics. In vitro gametogenesis: A review of ethical and policy questions. 2025 Jul 24. https://www.nuffieldbioethics.org/publication/in-vitro-gametogenesis-a-review-of-ethical-and-policy-questions/
- Singapore Medical Association. Medicine and the Law: Surrogacy. SMA News. 2021 Sep. https://www.sma.org.sg/news/2021/September/Medicine-and-the-Law-Surrogacy
- Le Goff A, Jeffries Hein R, Hart AN, Roberson I, Landecker HL. Anticipating in vitro gametogenesis: Hopes and concerns for IVG among diverse stakeholders. Stem Cell Reports. 2024;19(7):933-945. https://doi.org/10.1016/j.stemcr.2024.05.002
- Kraschel K. In Vitro–Derived Human Gametes as a Reproductive Technology: Scientific, Ethical, and Regulatory Implications. National Academies Press. 2023. https://doi.org/10.17226/27259
- Heng Boon Chin A. How IVG could challenge Singapore's laws on same-sex parenthood. BioNews. Progress Educational Trust. 2023 Jun 5. https://www.bionews.org.uk/page_170367
- Ministry of Health Singapore. Marriage and Parenthood Schemes. 2024. https://www.moh.gov.sg/managing-expenses/schemes-and-subsidies/marriage-and-parenthood-schemes/
- Coherent Market Insights. Donor Egg IVF (In-Vitro Fertilization) Market Trends. 2024. https://www.coherentmarketinsights.com/industry-reports/donor-egg-ivf-in-vitro-fertilization-market
- Heng Boon Chin A. Singapore needs to update regulation of frozen egg donation after permitting social egg freezing. Journal of Assisted Reproduction and Genetics. 2022;39(7):1497–1500. https://doi.org/10.1007/s10815-022-02526-y
- Kremer M, Glennerster R. Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases. Princeton University Press; 2004. https://doi.org/10.1515/9781400844289
- Barwick PJ, Xia H, Xia T. From Free Rider to Innovator: The Rise of China's Drug Development. National Bureau of Economic Research. 2026; w34977. https://doi.org/10.3386/w34977
- Evangelatos N, Reumann M, Lehrach H, Brand A. Clinical trial data as public goods: Fair trade and the virtual knowledge bank as a solution to the free rider problem. Public Health Genomics. 2016;19(4):211-218. https://doi.org/10.1159/000446101
- Ombelet W, Campo R. Affordable IVF for developing countries. Reproductive BioMedicine Online. 2007;15(3):257-265. https://doi.org/10.1016/s1472-6483(10)60337-9
- Wong PK, Singh A. From technology adopter to innovator: Singapore. In: Innovation Systems: Globalization, Change and Development. Edward Elgar Publishing; 2008. p. 87-118. https://doi.org/10.4337/9781848443990.00010
- Chen Y, Dong T. Health technology assessment and economic evaluation. Cost Effectiveness and Resource Allocation. 2021;19:58. https://doi.org/10.1186/s12962-021-00313-0